Updates are available Correction dated 2022-02-11
Click to view Correction: https://doi.org/10.1038/s43018-022-00343-8
-
Authors
Arrieta, Víctor A.
Chen, Andrew X.
Kane, J. Robert
Kang, Seong Jae
Kassab, Cynthia
Dmello, Crismita
Zhao, Junfei
Burdett, Kirsten B.
Upadhyayula, Pavan S.
Lee-Chang, Catalina
Shilati, Joseph
Jaishankar, Dinesh
Chen, Li
Gould, Andrew
Zhang, Daniel http://orcid.org/0000-0001-9962-9295
Yuan, Jinzhou
Zhao, Wenting
Ling, Xiaoyang
Burks, Jared K. http://orcid.org/0000-0002-6173-9074
Laffleur, Brice http://orcid.org/0000-0003-2904-9345
Amidei, Christina
Bruce, Jeffrey N. http://orcid.org/0000-0002-6844-0286
Lukas, Rimas V.
Yamaguchi, Jonathan T.
Cieremans, David
Rothschild, Gerson
Basu, Uttiya http://orcid.org/0000-0002-0185-7052
McCord, Matthew
Brat, Daniel J.
Zhang, Hui
Cooper, Lee A. D. http://orcid.org/0000-0002-3504-4965
Zhang, Bin
Sims, Peter
Cloughesy, Tim F. http://orcid.org/0000-0002-8656-7483
Prins, Robert http://orcid.org/0000-0002-6282-6583
Canoll, Peter
Stupp, Roger
Heimberger, Amy B. http://orcid.org/0000-0002-9970-8695
Horbinski, Craig http://orcid.org/0000-0001-8340-9992
Iwamoto, Fabio M. http://orcid.org/0000-0003-1397-9927
Rabadan, Raul http://orcid.org/0000-0001-7946-9255
Sonabend, Adam M. http://orcid.org/0000-0002-8347-1945
-
Funding
Funding for this research was provided by:
Consejo Nacional de Ciencia y Tecnología
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (1R01NS110703-01A1, 1R01NS110703-01A1, 1R01NS110703-01A1, 1R01NS110703-01A1, 1R01NS110703-01A1)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32GM007367)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1 R50 CA23707, U54CA209997, P50CA221747, R01-CA120813, 1R01-CA237418, P50CA221747, U54CA193313, U54CA209997, P50CA221747, P30CA060553)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (1R01AI09919, R01AI134988)
U.S. Department of Health & Human Services | NIH | NIH Office of the Director (5DP5OD021356-05)
- License Information
-
More Information
Article History
Received: 11 May 2021
Accepted: 20 August 2021
First Online: 29 November 2021
Change Date: 11 February 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s43018-022-00343-8
Competing interests
: F.M.I. is a consultant for Merck, Novocure, Regeneron, Abbvie, Alexion, Guidepoint and Tocagen. He has received clinical or research support (including equipment or material) from Bristol Myers Squibb and Merck. A.M.S., F.M.I. and R.R. are co-authors for the following patent filed by Columbia University: Systems and methods for predicting clinical responses to immunotherapies. A.M.S., V.A.A, F.M.I. and R.R. are co-authors of the following patent filed by Northwestern University: 5. Methods for treating glioblastoma. A.M.S. has received a consulting honorarium from Abbvie. R.R. is a member of the SAB of AimedBio and a founder of Genotwin. R.V.L. has received support from Roche-Genentech for meeting travel to present study results; honoraria for advisory boards for AstraZeneca, Abbvie and Ziopharm; and honoraria for medical editing for EBSCO publishing, Medlink Neurology and American Physician Institute. He has also received honoraria for consultation with Eisai and Abbvie, and honoraria for creating and presenting CME Board review material for the American Physician Institute. R.V.L. received drug support (but no additional support) from BMS for an investigator-initiated trial. A.B.H. is a consultant for Caris Life Sciences and WCG Oncology Advisory Board, receives royalties and milestone payments from Celldex Therapeutics and DNAtrix and receives clinical or research support (including equipment and materials) from Celularity, Codiak Biosciences, Moleculin and Carthera. The remaining authors declare no competing interests.
